TRANSDERM-NITRO 0.6 0.6 MG — DIN 02046156
NITROGLYCERIN : 0.6 MG · NOVARTIS PHARMACEUTICALS CANADA INC · PATCH (EXTENDED RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is TRANSDERM-NITRO 0.6?
TRANSDERM-NITRO 0.6 0.6 MG contains NITROGLYCERIN : 0.6 MG. It is listed in the Health Canada Drug Product Database under DIN 02046156, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as PATCH (EXTENDED RELEASE) for TRANSDERMAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Apr-2022. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is TRANSDERM-NITRO 0.6 used for?
Prevention of anginal attacks in patients with stable angina pectoris associated with coronary artery disease. Not for immediate relief of acute attacks.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Glyceryl Trinitrate cost around the world?
Glyceryl Trinitrate is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Kingdom | hospital | 12 | 12 | GBP███.██ |
| Australia | ex-manufacturer | 4 | 9 | AUD███.██ |
| Saudi Arabia | public | 5 | 8 | SAR███.██ |
| Luxembourg | reimbursement | 7 | 7 | EUR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| South Africa | single exit price | 3 | 4 | ZAR███.██ |
| Bahrain | retail (max) | 3 | 3 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 2 | CZK███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
53 pack listings across 43 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Glyceryl Trinitrate pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Glyceryl Trinitrate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Glyceryl Trinitrate, across 39 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 5 | 4 | MYLAN-NITRO PATCH 0.2, MYLAN-NITRO PATCH 0.4, MYLAN-NITRO PATCH 0.6, MYLAN-NITRO PATCH 0.8, MYLAN-NITRO SUBLINGUAL SPRAY | Sourceable in Canada |
| USPHARMA LTD | 4 | 4 | NITRO-DUR 0.2, NITRO-DUR 0.4, NITRO-DUR 0.6, NITRO-DUR 0.8 | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 3 | 3 | TRINIPATCH 0.2, TRINIPATCH 0.4, TRINIPATCH 0.6 | Sourceable in Canada |
| BAXTER CORPORATION | 3 | 2 | NITROGLYCERIN IN 5% DEXTROSE INJ.-100MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | NITROSTAT | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 1 | NITROJECT, NITROJECT INJ 1MG/ML | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | NITROGLYCERIN INJECTION USP, RHO-NITRO PUMPSPRAY | Sourceable in Canada |
| SANOFI-AVENTIS CANADA INC | 1 | 1 | NITROLINGUAL PUMPSPRAY | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 4 | 0 | TRANSDERM-NITRO 0.2, TRANSDERM-NITRO 0.4, TRANSDERM-NITRO 0.6, TRANSDERM-NITRO 0.8 | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 3 | 0 | MINITRAN | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | NITROGARD-SR TAB 1MG | No marketed DIN |
| METRO PHARM INC. | 1 | 0 | NITRONG SR SRT 2.6MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.6 MG |
|---|---|
| Dosage form | PATCH (EXTENDED RELEASE) |
| Route | TRANSDERMAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (refers to Dosage Forms section), but available in strengths of 0.2, 0.4, and 0.6 mg/hour. |
| Storage | Not explicitly detailed in provided text (refers to Storage and Stability section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Glyceryl Trinitrate |
|---|---|
| ATC code | C01DA02 |
| AHFS class | 24:12.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02046156 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2046156 |
| Brand name | TRANSDERM-NITRO 0.6 |
| Generic / active ingredient | NITROGLYCERIN : 0.6 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | C01DA02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01DA |
| Current status | CANCELLED POST MARKET |
| Status date | 05-Apr-2022 |
| Original market date | 1994-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply one patch daily (usually morning) for 12-14 hours followed by a 10-12 hour patch-free interval. Start at 0.2 mg/hr; max 0.8 mg/hr. Rotate application sites.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to nitrates; acute circulatory failure/shock; postural hypotension; left ventricular dysfunction; increased intracranial/intraocular pressure; severe anemia; use with PDE5 inhibitors.
Warnings and precautions
Remove patch before MRI or cardioversion (contains aluminum). May cause hypotension, syncope, or headache. Tolerance may develop with continuous use; requires nitrate-free interval.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 39 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-NITRO PATCH 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407442 |
| MYLAN-NITRO PATCH 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407450 |
| MYLAN-NITRO PATCH 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407469 |
| MYLAN-NITRO PATCH 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407477 |
| NITRO-DUR 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911910 |
| NITRO-DUR 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911902 |
| NITRO-DUR 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911929 |
| NITRO-DUR 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 02011271 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02145308 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02145316 |
2 · Same class — other molecules in ATC C01DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Glyceryl Trinitrate | APO-NITROGLYCERIN · MINITRAN · MINITRAN - PATCH TRD 72MG/26.6 SQ CM · MYLAN-NITRO PATCH 0.2 · +31 more | 39 | 18 | Yes |
| Isosorbide Mononitrate | APO-ISMN · DOM-ISMN · IMDUR · ISMN · +4 more | 8 | 3 | Yes |
| Isosorbide Dinitrate | CEDOCARD-SR SRT 20MG · CEDOCARD-SR SRT 40MG · CORADUR TAB 20MG · CORONEX · +16 more | 25 | 2 | Yes |
| Pentaerithrityl Tetranitrate | PERITRATE SA 80MG TAB · PERITRATE TAB 10MG · PERITRATE TAB 20MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01DX | Nesiritide · Vericiguat | 4 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRANSDERM-NITRO 0.6 called?
The same molecule, Glyceryl Trinitrate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NITRO-DUR | Latin | Saudi Arabia |
| Nitrolingual Pumpspray | Latin | Australia |
| Rectogesic | Latin | Bahrain, Iceland |
| Nitrocine | Latin | South Africa |
| Angised | Latin | South Africa |
| GLYTRIN Sublingual Spray | Latin | United Arab Emirates |
| NITROGLYCERIN SLOVAKOFARMA | Latin | Czechia |
| Nitrolingual | Latin | South Africa |
| Nitrolingual®-Spray | Latin | United Arab Emirates |
| NITROMINT | Latin | Czechia |
| Nitronal® aqueous | Latin | United Arab Emirates |
| Rectogesic® | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.